Comprehensive clinical trial delivery across Phase I–III with a focus on quality and efficiency.
hVIVO is a specialist in cardiometabolic clinical studies, offering a broad spectrum of pharmacodynamic assessments in the indication of obesity, insulin resistance, endothelial dysfunction, diabetes, lipid disorders, hypertension, or Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD). Supported by a broad network of medical specialists in endocrinology, diabetes, cardiology, hepatology, and nephrology. With over 30 years of scientific leadership from Professor Thomas Forst and access to respective patient populations, hVIVO delivers end-to-end trial support spanning PK/PD consultancy and full-service clinical operations
If you are planning a Cardiometabolic trial talk to our team tody.
Metabolic Assessments
Fat Tissue Distribution /Energy Expenditure
Vascular / Endothelial Function
Biomarker assessments
Indications
Obesity
Insulin resistance
Metabolic syndrome
Metabolic dysfunction associated steatotic liver diseases (MASLD),
Diabetes mellitus (type 1 and type 2)
Lipid disorders
Hypertension
Special Populations
Elderly
Pharmacogenetic Normal, Intermediate, Excessive Metabolisers
Gender Trials (female, post-menopausal)
Renal Impairment
Hepatic Impairment
Patient Populations
Diabetic
Obese
Women’s Health (PCO, Endometriosis)
Dermatology (Atopic dermatitis, Psoriasis)
Hypertension
Hypercholesterolemia
The hVIVO group provides end-to-end drug development support and has standalone and full-service offerings spanning regulatory strategy and submission support, CMC and PK/PD consultancy, project management, data management, and biostatistics services. With an established database of over 400,000 participants, including participants with cardiovascular and metabolic disease, hVIVO can ensure your studies run seamlessly from start to finish.
hVIVO provides a panel of metabolic, endocrinological and vascular testing for the assessments pharmacodynamic effects in cardiometabolic clinical trials.
Yes, including continuous glucose monitoring, meal tests, insulin resistance and beta cell function testing, and energy expenditure assessments.
FibroScan®, MRI‑PDFF, and DEXA are available for liver and body composition imaging.
Obesity, insulin resistance, metabolic syndrome, metabolic dysfunction associated steatotic liver diseases (MASLD), diabetes mellitus (type 1 and type 2), lipid disorders, hypertension.
Yes, including early‑phase studies, PK/PD consultancy, and full clinical operations.
If you're a potential customer, find out how hVIVO can help you.
